| Autor: |
Ying Y; School of Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China.; Marshall Laboratory of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen 518060, China., Wang M; School of Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China.; College of Pharmacy, Shenzhen Technology University, Shenzhen, 518000, China., Chen Y; School of Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China., Li M; School of Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China., Ma C; School of Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China., Zhang J; School of Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China., Huang X; School of Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China., Jia M; School of Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China., Zeng J; School of Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China., Wang Y; School of Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China., Li L; Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong 00000, China., Wang X; School of Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China., Tao Q; Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong 00000, China., Shu XS; School of Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China.; Marshall Laboratory of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen 518060, China. |
| Abstrakt: |
Dysregulated epigenetic and transcriptional programming due to abnormalities of transcription factors (TFs) contributes to and sustains the oncogenicity of cancer cells. Here, we unveiled the role of zinc finger protein 280C (ZNF280C), a known DNA damage response protein, as a tumorigenic TF in colorectal cancer (CRC), required for colitis-associated carcinogenesis and Apc deficiency–driven intestinal tumorigenesis in mice. Consistently, ZNF280C silencing in human CRC cells inhibited proliferation, clonogenicity, migration, xenograft growth, and liver metastasis. As a C2H2 (Cys2-His2) zinc finger-containing TF, ZNF280C occupied genomic intervals with both transcriptionally active and repressive states and coincided with CCCTC-binding factor (CTCF) and cohesin binding. Notably, ZNF280C was crucial for the repression program of trimethylation of histone H3 at lysine 27 (H3K27me3)-marked genes and the maintenance of both focal and broad H3K27me3 levels. Mechanistically, ZNF280C counteracted CTCF/cohesin activities and condensed the chromatin environment at the cis elements of certain tumor suppressor genes marked by H3K27me3, at least partially through recruiting the epigenetic repressor structural maintenance of chromosomes flexible hinge domain-containing 1 (SMCHD1). In clinical relevance, ZNF280C was highly expressed in primary CRCs and distant metastases, and a higher ZNF280C level independently predicted worse prognosis of CRC patients. Thus, our study uncovered a contributor with good prognostic value to CRC pathogenesis and also elucidated the essence of DNA-binding TFs in orchestrating the epigenetic programming of gene regulation. |
